Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CC-122 |
Trade Name | |
Synonyms | Avadomide |
Drug Descriptions |
Avadomide (CC-122) is an immunomodulatory drug analog that targets Cereblon and promotes degradation of several proteins, including Ikaros and Aiolos, leading to decreased B-cell proliferation and decreased tumor angiogenesis (Blood Dec 2014, 124 (21) 3500). |
DrugClasses | |
CAS Registry Number | 1015474-32-4 |
NCIT ID | C160786 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CC-122 | CC-122 | 0 | 2 |
CC-122 + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate | CC-122 Cyclophosphamide Prednisone Rituximab Vincristine Sulfate | 0 | 1 |
CC-122 + Nivolumab | CC-122 Nivolumab | 0 | 2 |
CC-122 + Onatasertib | CC-122 Onatasertib | 0 | 1 |
CC-122 + Sorafenib | CC-122 Sorafenib | 0 | 1 |
CC-122 + Spebrutinib | CC-122 Spebrutinib | 0 | 1 |